基于唑来膦酸对破骨细胞抑制特征的实验研究
本研究目的为获得不同浓度唑来膦酸对破骨细胞抑制作用的特征及最低有效浓度。取C57小鼠骨髓单核细胞并诱导分化破骨细胞。实验组分别加入唑来膦酸的浓度为1×10^-8、1×10^-7、1×10^-6、1×10^5、1×10^-4mol/L;同时设置不含任何双膦酸盐的对照组。计数多核细胞、通过滤网细胞、附壁细胞、骨吸收陷窝,观察不同浓度唑来膦酸对破骨细胞抑制作用的特征。发现唑来膦酸抑制体外破骨细胞形成的最低有效浓度为1/1×10^-6mol/L;在1×10^-5mol/L浓度下抑制破骨细胞迁移和骨吸收的作用更为显著;在1×10^-4mol/L浓度下效果进一步增强,但高浓度唑来膦酸抑制破骨细胞能力的增强...
Saved in:
Published in | Sheng wu yi xue gong cheng xue za zhi Vol. 34; no. 1; pp. 78 - 82 |
---|---|
Main Author | |
Format | Journal Article |
Language | Chinese English |
Published |
中国四川
四川大学华西医院
25.02.2017
|
Subjects | |
Online Access | Get full text |
ISSN | 1001-5515 |
DOI | 10.7507/1001-5515.201601041 |
Cover
Summary: | 本研究目的为获得不同浓度唑来膦酸对破骨细胞抑制作用的特征及最低有效浓度。取C57小鼠骨髓单核细胞并诱导分化破骨细胞。实验组分别加入唑来膦酸的浓度为1×10^-8、1×10^-7、1×10^-6、1×10^5、1×10^-4mol/L;同时设置不含任何双膦酸盐的对照组。计数多核细胞、通过滤网细胞、附壁细胞、骨吸收陷窝,观察不同浓度唑来膦酸对破骨细胞抑制作用的特征。发现唑来膦酸抑制体外破骨细胞形成的最低有效浓度为1/1×10^-6mol/L;在1×10^-5mol/L浓度下抑制破骨细胞迁移和骨吸收的作用更为显著;在1×10^-4mol/L浓度下效果进一步增强,但高浓度唑来膦酸抑制破骨细胞能力的增强已趋于平缓。提示临床应用中要注意选择合适浓度和剂量的唑来膦酸进行治疗。 |
---|---|
Bibliography: | This study is to investigate the inhibitory effect of different concentrations of zoledronic acid on the activity of osteoclasts, to obtain characteristics on inhibitory effect and to find the lowest effective concentration of zoledronic acid. Marrow cells of C57 mice (6 weeks) were cultured in vitro. Osteoclasts were induced by single nuclear cells. According to the concentration of zoledronic acid, we set up the experimental group with five different concentrations, i.e. 1×10^-8 mol/L, 1×10^-7 mol/L, 1×10^-6 mol/L, 1×10^-5 mol/L, and 1×10 ^-4 mol/L. The control group did not contain any bisphosphonate. By tartrate resistant acid phosphatase staining, the number of multinuclear cells, cells through the filter and bone resorption lacune were counted. Five days after the cultivation, the number of multinuclear cells in the experimental group decreased with the increase of concentration of zoledronic acid. Inhibition on the formation of osteoclasts in vitro was effective at 1 × 10^-6 mol/L. At the concentration |
ISSN: | 1001-5515 |
DOI: | 10.7507/1001-5515.201601041 |